Late Breaking Abstract - Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia: a randomised clinical trial

E. Wittermans (Nieuwegein, Netherlands), S. Vestjens (Nieuwegein, Netherlands), S. Spoorenberg (Nieuwegein, Netherlands), W. Blok (Amsterdam, Netherlands), J. Grutters (Nieuwegein, Netherlands), R. Janssen (Nijmegen, Netherlands), G. Rijkers (Middelburg, Netherlands), F. Smeenk (Eindhoven, Netherlands), P. Voorn (Nieuwegein, Netherlands), E. Van De Garde (Nieuwegein, Netherlands), W. Bos (Nieuwegein, Netherlands)

Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Session: ALERT: Infection in adults and children
Session type: Clinical trials session
Number: 4132
Disease area: Respiratory infections

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Wittermans (Nieuwegein, Netherlands), S. Vestjens (Nieuwegein, Netherlands), S. Spoorenberg (Nieuwegein, Netherlands), W. Blok (Amsterdam, Netherlands), J. Grutters (Nieuwegein, Netherlands), R. Janssen (Nijmegen, Netherlands), G. Rijkers (Middelburg, Netherlands), F. Smeenk (Eindhoven, Netherlands), P. Voorn (Nieuwegein, Netherlands), E. Van De Garde (Nieuwegein, Netherlands), W. Bos (Nieuwegein, Netherlands). Late Breaking Abstract - Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia: a randomised clinical trial. 4132

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial
Source: Eur Respir J, 58 (2) 2002535; 10.1183/13993003.02535-2020
Year: 2021



Late Breaking Abstract - Effect of adjunctive tobramycin inhalation therapy in the treatment of ventilator-associated pneumonia: findings from the randomized VAPORISE trial
Source: International Congress 2019 – Recent developments in intensive care unit medicine
Year: 2019

Late Breaking Abstract - Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children: a randomized controlled trial
Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Year: 2020




Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial
Source: International Congress 2015 – Acute critical care: news from the ICU
Year: 2015



LATE-BREAKING ABSTRACT: Intravenous infusion of Chinese medicine xuebijing significantly improved clinical outcome in severe pneumonia patients in a multiple center randomized controlled clinical trials
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016



Late Breaking Abstract: High-dose vitamin D3 during intensive phase treatment of pulmonary tuberculosis: A double-blind randomised controlled trial
Source: Annual Congress 2010 - Clinical tuberculosis
Year: 2010

Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study
Source: International Congress 2017 – Late-breaking studies in asthma and COPD
Year: 2017



A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen
Source: Eur Respir J 2001; 18: Suppl. 33, 189s
Year: 2001

Procalcitonin-guided antibiotic therapy in acute exacerbations of COPD (AECOPD): a randomised trial - The ProCOLD Study
Source: Eur Respir J 2005; 26: Suppl. 49, 464s
Year: 2005

Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet?
Source: Eur Respir J 2013; 41: 5-6
Year: 2013


Efficacy of azithromycin in severe asthma from the AMAZES randomised trial
Source: ERJ Open Res, 5 (4) 00056-2019; 10.1183/23120541.00056-2019
Year: 2019



Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019




Randomized, controlled trial of efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants
Source: Eur Respir J 2006; 28: Suppl. 50, 488s
Year: 2006

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial
Source: Eur Respir J, 56 (6) 2002808; 10.1183/13993003.02808-2020
Year: 2020



Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives
Source: Eur Respir J 2004; 24: Suppl. 48, 185s
Year: 2004

Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015

Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013



Late Breaking Abstract - Azithromycin for acute COPD exacerbations requiring hospitalization – the BACE trial results
Source: International Congress 2018 – Clinical trials in COPD: new results
Year: 2018



Supplementation of N-acetylcysteine as an adjuvant in treatment of newly diagnosed pulmonary tuberculosis patients: A prospective, randomized double blind, placebo controlled study
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Year: 2013

Late Breaking Abstract - Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid - Data from 38,820 outpatients.
Source: International Congress 2019 – Comorbidities galore in respiratory patients
Year: 2019